期刊文献+

复方苦参注射液治疗浆细胞性乳腺炎22例临床疗效观察

Clinical effect observation on compound sophora injection in the treatment of 22 cases of plasma cell mastitis
下载PDF
导出
摘要 目的归纳复方苦参注射液治疗浆细胞性乳腺炎(PCM)患者临床疗效及相关理化检查的数据,验证其对该病是否具有确切疗效。方法 37例浆细胞性乳腺炎患者,随机分为两组,其中对照组15例,实验组22例。对照组采用常规西药加中药内服治疗,实验组采用复方苦参注射液加中药内服治疗。收集治疗前后相关数据,进行统计分析。结果对照组总有效率66.67%,实验组总有效率86.36%,差异有统计学意义(P<0.05)。治疗前后理化检查分析:血常规、C反应蛋白治疗前后差异无统计学意义(P>0.05)。免疫球蛋白治疗前后差异具有统计学意义(P<0.01)。结论复方苦参注射液治疗浆细胞性乳腺炎疗效满意,值得推广。 Objective To summarize clinical effect and related examination data of compound sophora injection in the treatment of 37 cases of plasma cell mastitis(PCM) to validate its definite therapeutic effect. Methods Divided 37 PCM patients into two groups, 15 cases in control group, 22 cases in experimental group. The control group was treated with conventional western medicine treatment. The experimental group adopted compound sophora injection plus traditional Chinese medicine treatment. Collected the data to analyze. Results Total effective rate of control group was 66.67%, the total efficiency of experimental group was 86.36%(P〈0.05). Physical and chemical inspection analysis before and after treatment:blood routine, C reactive protein(P〉0.05), differences were not statistically significant(P〈0.01). Conclusion Compound sophora injection has a good effect in the treatment of PCM, so it is worthy of clinical promotion.
作者 郭琪 郭宇飞
出处 《中国实用医药》 2014年第22期31-33,共3页 China Practical Medicine
关键词 复方苦参注射液 浆细胞性乳腺炎 Compound sophora injection Plasma cell mastitis
  • 相关文献

参考文献3

二级参考文献33

  • 1石松魁.乳腺导管扩张症的诊断及治疗[J].中国实用外科杂志,1994,14(6):323-324. 被引量:53
  • 2石松魁,牛昀,张景华,胡锡禄.乳腺导管扩张症(附187例报告)[J].中国普通外科杂志,1995,4(6):329-331. 被引量:12
  • 3William J,Gradishar,Sergei Tjulandin,et al.Phase Ⅲ trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer[J].J Clin Oncol,2005,23(31):7794-7803.
  • 4Ellis M,Hayes DF,Lippman ME.Treatment of metastatic breast cancer[A].Harris JR,Lippman ME,Morrow M,et al.Diseases of the breast[M].Philadelphia:Lippincott Williams & Wilkins,2004.
  • 5Colozza M,de Azambuja E,Personeni N,et al.Achievements in systemic therapies in the pregenomic era in metastatic breast cancer[J].Oncologist,2007,12:253-270.
  • 6O' Brien ME,Wigler N,Inbar M,et al.Reduced cardiotoxicity and comparable efficacy in a phase Ⅲ trial of pegylated liposomal doxorubicin HCl(CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer[J].Ann Oncol,2004,15:440-449.
  • 7Biganzoli L,Coleman R,Minisini A,et al.A joined analysis of two European Organization for the Research and Treatment of Cancer(EORTC) studies to evaluate the role of pegylated liposomal doxorubicin(Caelyx) in the treatment of elderly patients with metastatic breast cancer[J].Crit Rev Oncol Hematol,2007,61:84-89.
  • 8Batist G,Harris L,Azarnia N,et al.Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin:Results of a retrospective analysis[J].Anticancer Drugs,2006,17:587-595.
  • 9Bria E,Giannarelli D,Felici A,et al.Taxanes with anthracyclines as first-line chemotherapy for metastatic breast carcinoma[J].J Clin Oncol,2005,103:672-679.
  • 10Sledge GW,Neuberg D,Bernardo P,et al.Phase Ⅲ trial of doxorubicin,paclitaxel,and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer:An intergroup trial(E1193)[J].J Clin Oncol,2003,21:588-592.

共引文献69

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部